Program
pacritinib
Also written as “Pacritinib”, “SB1518” and “CYP450 Cocktail and Transporter Substrates with Pacritinib”.
Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Leukemia, Myelomonocytic, Chronic · COVID-19 · Hodgkin Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Swedish Orphan Biovitrum | 122 open or running | phase 3since Jan 18, 2013 | Jan 18, 2013 | Dec 30, 2026phase 2 · NCT06782373 |
| S*BIO | 40 open or running | phase 2since Jul 20, 2008 | Jul 20, 2008 | none ahead |
| Takeda | 10 open or running | phase 2since Oct 21, 2015 | Oct 21, 2015 | none ahead |
| Theradex | 11 open or running | phase 2since Jun 5, 2025 | Jun 5, 2025 | Jul 2028phase 2 · NCT07033598 |
Also a collaborator on its studies: psi-cro, ppd-development-lp, covance, sgs-s-a and qps-qualitix.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2008First study: phase 2 study in Leukemia, Myeloid, AcuteNew to S*BIOS*BIO · NCT00719836 · 76 enrolled · United States
- Aug 22, 2008Phase 1 study in LymphomaS*BIO · NCT00741871 · 35 enrolled · United States
- Sep 2, 2008Phase 2 study in Primary MyelofibrosisS*BIO · NCT00745550 · 55 enrolled · United States, Australia
- Dec 16, 2010Phase 2 study in Hodgkin DiseaseS*BIO · NCT01263899 · 28 enrolled · United States, Canada
- Jan 18, 2013Swedish Orphan Biovitrum's first study: phase 3 study in Primary MyelofibrosisNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT01773187 · 327 enrolled · United States, Australia, Belgium and more
- Feb 3, 2014Phase 3 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT02055781 · 311 enrolled · United States, Australia, Belgium and more
- Oct 21, 2015Takeda's first study: phase 2 study in Primary MyelofibrosisNew to TakedaTakeda · NCT02584777
- May 3, 20165 phase 1 studiesSwedish Orphan Biovitrum · NCT02807116, NCT02807077, NCT02807051 and 2 more
- May 17, 2017Phase 3 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT03165734 · 407 enrolled · United States, Australia, Belarus and more
- May 22, 2020Phase 2 study in COVID-19Swedish Orphan Biovitrum · NCT04404361 · 200 enrolled · United States
- May 10, 2021Phase 2 study in Primary MyelofibrosisSwedish Orphan Biovitrum · NCT04884191 · 165 enrolled · United States, France, Hungary and more
- Dec 12, 2022Phase 1 study in Drug InteractionsSwedish Orphan Biovitrum · NCT05657613 · 60 enrolled · United States
- Jan 7, 2025Phase 2 study in VEXAS syndromeSwedish Orphan Biovitrum · NCT06782373 · 156 planned · United States, Canada, France and more
- Jun 5, 2025Theradex's first study: phase 2 study in Leukemia, Myelomonocytic, ChronicNew to TheradexTheradex · NCT07033598 · 66 planned · United States, United Kingdom
Ahead
- Dec 30, 2026Primary completion: phase 2 study in VEXAS syndromeSwedish Orphan Biovitrum · NCT06782373
- Jul 2028Primary completion: phase 2 study in Leukemia, Myelomonocytic, ChronicTheradex · NCT07033598
TargetBeta
“The citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
“Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07033598Leukemia, Myelomonocytic, Chronic · United States, United Kingdom | 2 | Recruiting | Theradex | Jul 2028 | 66 |
| NCT06782373VEXAS syndrome · United States, Canada, France and more | 2 | Recruiting | Swedish Orphan Biovitrum | Dec 30, 2026 | 156 |
| NCT05657613Drug Interactions · United States | 1 | Completed | Swedish Orphan Biovitrum | Jun 8, 2023 | 60 |
| NCT04884191Primary Myelofibrosis · United States, France, Hungary and more | 2 | Completed | Swedish Orphan Biovitrum | Sep 4, 2019 | 165 |
| NCT04404361COVID-19 · United States | 2 | Terminated | Swedish Orphan Biovitrum | Sep 21, 2021 | 200 |
| NCT03165734Primary Myelofibrosis · United States, Australia, Belarus and more | 3 | Active, not recruiting | Swedish Orphan Biovitrum | Oct 5, 2026 | 407 |
| NCT02807116Healthy Subjects · United States | 1 | Completed | Swedish Orphan Biovitrum | Feb 2015 | 18 |
| NCT02807077Primary Myelofibrosis · Germany, Moldova, Republic of, Romania | 1 | Completed | Swedish Orphan Biovitrum | Jul 2015 | 40 |
| NCT02807051Drug Interaction Study · United States | 1 | Completed | Swedish Orphan Biovitrum | Oct 2014 | 20 |
| NCT02803762Healthy · Netherlands | 1 | Completed | Swedish Orphan Biovitrum | Oct 2014 | 6 |
| NCT02765724Primary Myelofibrosis · Germany, Moldova, Republic of | 1 | Completed | Swedish Orphan Biovitrum | Jun 2015 | 28 |
| NCT02584777Primary Myelofibrosis | 2 | Withdrawn | Takeda | Sep 30, 2017 | 0 |
| NCT02055781Primary Myelofibrosis · United States, Australia, Belgium and more | 3 | Terminated | Swedish Orphan Biovitrum | Apr 2016 | 311 |
| NCT01773187Primary Myelofibrosis · United States, Australia, Belgium and more | 3 | Terminated | Swedish Orphan Biovitrum | Jan 2015 | 327 |
| NCT01263899Hodgkin Disease · United States, Canada | 2 | Completed | S*BIO | Feb 2012 | 28 |
| NCT00745550Primary Myelofibrosis · United States, Australia | 2 | Completed | S*BIO | Jan 2012 | 55 |
| NCT00741871Lymphoma · United States | 1 | Completed | S*BIO | Oct 2011 | 35 |
| NCT00719836Leukemia, Myeloid, Acute · United States | 2 | Completed | S*BIO | Jan 2012 | 76 |
How it is read
Names in the registry
- “Pacritinib”, 13 entries
- “SB1518”, 4 entries
- “CYP450 Cocktail and Transporter Substrates with Pacritinib”, 1 entry
- “Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib”, 1 entry
- “Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 8 studies
- Hematologic Neoplasms, 1 study
- Leukemia, Myelomonocytic, Chronic, 1 study
- COVID-19, 1 study
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.